Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
Participants have not received systemic therapy (chemotherapy, radiotherapy, chemoradiation) for ES-SCLC.
Treatment-free for at least 6 months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for limited-stage SCLC
Have at least one measurable lesion as the targeted lesion based on RECIST V1.1.
Eastern Cooperative Oncology Group performance status of 0 or 1.
Adequate organ function
You may not be if
known active CNS lesions, including brainstem, meningeal, or spinal cord metastases or compression
Leptomeningeal disease
Clinically significant risk of hemorrhage or fistula
history of another malignancy within 3 years
active autoimmune diseases requiring systemic treatment within the past 2 years
Clareo Health | Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
